Diagnostic and prognostic value of CD44v9 and TIM3 expression in CK<sup>‑</sup> and CK<sup>+</sup> regions in gastric cancer tissues

Wang,Xiaofei; Lu,Lin; Yang,Ruidong; Wang,Zhiwu; Li,Qingke; Li,Jingwu; Liu,Yankun

doi:10.3892/ol.2024.14612

Diagnostic and prognostic value of CD44v9 and TIM3 expression in CK^‑ and CK⁺ regions in gastric cancer tissues

Authors:
- Xiaofei Wang
- Lin Lu
- Ruidong Yang
- Zhiwu Wang
- Qingke Li
- Jingwu Li
- Yankun Liu
View Affiliations

Affiliations: School of Clinical Medicine, North China University of Science and Technology, Tangshan, Hebei 063200, P.R. China, Department of Medical Molecular Diagnosis, Tangshan People's Hospital, Tangshan, Hebei 063001, P.R. China, Department of Pathology, Luanzhou City People's Hospital, Tangshan, Hebei 063004, P.R. China, Second Department of Radiotherapy and Chemotherapy, Tangshan People's Hospital, Tangshan, Hebei 063001, P.R. China, Department of Gastrointestinal Surgery, Tangshan People's Hospital, Tangshan, Hebei 063001, P.R. China, Hebei Province Key Laboratory of Molecular Oncology, Tangshan People's Hospital, Tangshan, Hebei 063001, P.R. China
Published online on: August 6, 2024 https://doi.org/10.3892/ol.2024.14612
Article Number: 479
Copyright: © Wang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The specificity and sensitivity of the current diagnostic and prognostic biomarkers for gastric cancer (GC) are limited. The present study aimed to evaluate the diagnostic and prognostic significance of cluster‑of‑differentiation gene 44 variant isoform 9 (CD44v9) and T cell immunoglobulin and mucin domain‑containing protein 3 (TIM3) expression levels alone or combined in the tumor tissues of patients with GC and reveal the roles of CD44v9 and TIM3 in the cytokeratin (CK)⁺ and CK^‑ regions. Multiplex immunofluorescence staining was performed for CD44v9, TIM3 and CK using a tissue microarray. The tissues were divided into three regions based on CK expression: Total, CK⁺, and CK^‑ regions. The diagnostic and prognostic value was evaluated using receiver operating characteristic curves, Kaplan‑Meier and Cox regression analyses. The results demonstrated that the density of cells expressing CD44v9, TIM3 and co‑expressing CD44v9 and TIM3 (CD44v9/TIM3) in both the CK⁺ and CK‑ regions of tumor tissues was significantly higher than those in normal tissues (P<0.001). Moreover, the expression of CD44v9 in the CK^‑ region was significantly positively correlated with age and tumor grade (P<0.05), and the expression of CD44v9/TIM3 in the CK‑ region of tumor tissues was significantly positively correlated with age, tumor grade and metastasis (P<0.05). Furthermore, the area under the curve for TIM3 expression in the CK⁺ region was 0.709, with a sensitivity of 45.83% and a specificity of 85.54% (P<0.001). High expression of CD44v9 in the CK^‑ region was also significantly associated with poor survival and independently predicted a poor prognosis in patients with GC (hazard ratio, 2.387; 95% confidence interval, 1.384‑4.118; P<0.01). In conclusion, dividing tissue regions based on CK expression is important for the diagnosis of GC. The expression of TIM3 in the CK⁺ region demonstrated diagnostic potential for GC, and high expression of CD44v9 in the CK^‑ region was an independent prognostic risk factor for patients with GC.

View Figures

View References

1	Sedeta E, Sung H, Laversanne M, Bray F and Jemal A: Recent mortality patterns and time trends for the major cancers in 47 countries worldwide. Cancer Epidemiol Biomarkers Prev. 32:894–905. 2023. View Article : Google Scholar : PubMed/NCBI
2	Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020: Globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2021. View Article : Google Scholar : PubMed/NCBI
3	Matsuzaki J, Tsugawa H and Suzuki H: Precision medicine approaches to prevent gastric cancer. Gut and Liver. 15:3–12. 2021. View Article : Google Scholar : PubMed/NCBI
4	Wang FH, Zhang XT, Tang L, Wu Q, Cai MY, Li YF, Qu XJ, Qiu H, Zhang YJ, Ying JE, et al: The Chinese society of clinical oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer. Cancer Commun (Lond). 44:127–172. 2023. View Article : Google Scholar : PubMed/NCBI
5	Morath I, Hartmann TN and Orian-Rousseau V: CD44: More than a mere stem cell marker. Int J Biochem Cell Biol. 81:166–173. 2016. View Article : Google Scholar : PubMed/NCBI
6	Choi ES, Kim H, Kim HP, Choi Y and Goh SH: CD44v8-10 as a potential theranostic biomarker for targeting disseminated cancer cells in advanced gastric cancer. Sci Rep. 7:49302017. View Article : Google Scholar : PubMed/NCBI
7	Harn HJ, Ho LI, Chang JY, Wu CW, Jiang SY, Lee HS and Lee WH: Differential expression of the human metastasis adhesion molecule CD44V in normal and carcinomatous stomach mucosa of Chinese subjects. Cancer. 75:1065–71. 1995. View Article : Google Scholar : PubMed/NCBI
8	Hirata K, Suzuki H, Imaeda H, Matsuzaki J, Tsugawa H, Nagano O, Asakura K, Saya H and Hibi T: CD44 variant 9 expression in primary early gastric cancer as a predictive marker for recurrence. Br J Cancer. 109:379–386. 2013. View Article : Google Scholar : PubMed/NCBI
9	Go SI, Ko GH, Lee WS, Kim RB, Lee JH, Jeong SH, Lee YJ, Hong SC and Ha WS: CD44 variant 9 serves as a poor prognostic marker in early gastric cancer, but not in advanced gastric cancer. Cancer Res Treat. 48:142–152. 2016. View Article : Google Scholar : PubMed/NCBI
10	Yamakawa Y, Kusuhara M, Terashima M, Kinugasa Y, Sugino T, Abe M, Mochizuki T, Hatakeyama K, Kami K and Yamaguchi K: CD44 variant 9 expression as a predictor for gastric cancer recurrence: Immunohistochemical and metabolomic analysis of surgically resected tissues. Biomed Res. 38:41–52. 2017. View Article : Google Scholar : PubMed/NCBI
11	Akamine T, Tagawa T, Ijichi K, Toyokawa G, Takamori S, Hirai F, Okamoto T, Oda Y and Maehara Y: The significance of CD44 variant 9 in resected lung adenocarcinoma: Correlation with pathological early-stage and FGFR mutation. Ann Surg Oncol. 26:1544–1551. 2019. View Article : Google Scholar : PubMed/NCBI
12	Hagiwara M, Kikuchi E, Tanaka N, Kosaka T, Mikami S, Saya H and Oya M: Variant isoforms of CD44 involves acquisition of chemoresistance to cisplatin and has potential as a novel indicator for identifying a cisplatin-resistant population in urothelial cancer. BMC Cancer. 18:1132018. View Article : Google Scholar : PubMed/NCBI
13	Ogihara K, Kikuchi E, Okazaki S, Hagiwara M, Takeda T, Matsumoto K, Kosaka T, Mikami S, Saya H and Oya M: Sulfasalazine could modulate the CD44v9-xCT system and enhance cisplatin-induced cytotoxic effects in metastatic bladder cancer. Cancer Sci. 110:1431–141. 2019. View Article : Google Scholar : PubMed/NCBI
14	Jogo T, Oki E, Nakanishi R, Ando K, Nakashima Y, Kimura Y, Saeki H, Oda Y, Maehara Y and Mori M: Expression of CD44 variant 9 induces chemoresistance of gastric cancer by controlling intracellular reactive oxygen spices accumulation. Gastric Cancer. 24:1089–1099. 2021. View Article : Google Scholar : PubMed/NCBI
15	Zhang Y, Gao J, He Y, Qi Z, Qian L, Chen W, Xu H, Yue Y, Mao X, Guo S, et al: Vascular normalization was associated with colorectal tumor regression upon anti-PD-L1 combinational therapy. J Immunology Res. 2023:58670472023. View Article : Google Scholar : PubMed/NCBI
16	Solier S, Müller S, Cañeque T, Versini A, Mansart A, Sindikubwabo F, Baron L, Emam L, Gestraud P, Pantoș GD, et al: A druggable copper-signalling pathway that drives inflammation. Nature. 617:386–394. 2023. View Article : Google Scholar : PubMed/NCBI
17	He Y, Cao J, Zhao C, Li X, Zhou C and Hirsch FR: TIM-3, a promising target for cancer immunotherapy. Onco Targets Ther. 11:7005–7009. 2018. View Article : Google Scholar : PubMed/NCBI
18	Wang Y, Zhao E, Zhang Z, Zhao G and Cao H: Association between Tim-3 and Gal-9 expression and gastric cancer prognosis. Oncol Rep. 40:2115–2126. 2018.PubMed/NCBI
19	Qin S, Dong B, Yi M, Chu Q and Wu K: Prognostic values of TIM-3 expression in patients with solid tumors: A meta-analysis and database evaluation. Front Oncol. 10:12882020. View Article : Google Scholar : PubMed/NCBI
20	Chen K, Gu Y, Cao Y, Fang H, Lv K, Liu X, He X, Wang J, Lin C, Liu H, et al: TIM3+ cells in gastric cancer: Clinical correlates and association with immune context. Br J Cancer. 126:100–108. 2021. View Article : Google Scholar : PubMed/NCBI
21	Wu Y, Chen YQ, Shi TG, Tan NJ and Chen WC: Study of immunophenotypic characteristics, clinicopathological parameters and prognosis in gastric cancer microenvironment. Zhonghua Yi Xue Za Zhi. 103:2786–2794. 2023.(In Chinese). PubMed/NCBI
22	Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL and Trotti A: AJCC cancer staging manual. Seventh edition. Springer; New York: pp. 117–126. 2010
23	Lin L, Li H, Wang X, Wang Z, Su G, Zhou J, Sun S, Ma X, Chen Y, You C, et al: Components of the tumor immune microenvironment based on m-IHC correlate with prognosis and subtype of triple-negative breast cancer. Cancer Med. 12:21639–21650. 2023. View Article : Google Scholar : PubMed/NCBI
24	Zuo WW, Zhao CF, Li Y, Sun HY, Ma GM, Liu YP and Kang S: High expression of PARP1 in tumor and stroma cells predicts different prognosis and platinum resistance in patients with advanced epithelial ovarian cancer. Front Oncol. 12:9314452022. View Article : Google Scholar : PubMed/NCBI
25	Moll R, Divo M and Langbein L: The human keratins: Biology and pathology. Histochem Cell Biol. 129:705–733. 2008. View Article : Google Scholar : PubMed/NCBI
26	Chu PG and Weiss LM: Keratin expression in human tissues and neoplasms. Histopathology. 40:403–439. 2002. View Article : Google Scholar : PubMed/NCBI
27	Antonio MJ, Zhang C and Le A: Different tumor microenvironments lead to different metabolic phenotypes. Adv Exp Med Biol. 1311:137–147. 2021. View Article : Google Scholar : PubMed/NCBI
28	Hui L and Chen Y: Tumor microenvironment: Sanctuary of the devil. Cancer Lett. 368:7–13. 2015. View Article : Google Scholar : PubMed/NCBI
29	Taube JM, Akturk G, Angelo M, Engle EL, Gnjatic S, Greenbaum S, Greenwald NF, Hedvat CV, Hollmann TJ, Juco J, et al: The society for immunotherapy of cancer statement on best practices for multiplex immunohistochemistry (IHC) and immunofluorescence (IF) staining and validation. J Immunother Cancer. 8:e0001552020. View Article : Google Scholar : PubMed/NCBI
30	Harms PW, Frankel TL, Moutafi M, Rao A, Rimm DL, Taube JM, Thomas D, Chan MP and Pantanowitz L: Multiplex immunohistochemistry and immunofluorescence: A practical update for pathologists. Mod Pathol. 36:1001972023. View Article : Google Scholar : PubMed/NCBI
31	Stack EC, Wang C, Roman KA and Hoyt CC: Multiplexed immunohistochemistry, imaging, and quantitation: A review, with an assessment of Tyramide signal amplification, multispectral imaging and multiplex analysis. Methods. 70:46–58. 2014. View Article : Google Scholar : PubMed/NCBI
32	Granier C, Vinatier E, Colin E, Mandavit M, Dariane C, Verkarre V, Biard L, El Zein R, Lesaffre C, Galy-Fauroux I, et al: Multiplexed immunofluorescence analysis and quantification of intratumoral PD-1+ Tim-3+ CD8+ T Cells. J Vis Exp. 132:566062018.
33	Liu T, Sun L, Zhang Y, Wang Y and Zheng J: Imbalanced GSH/ROS and sequential cell death. J Biochemical Mol Toxicol. 36:e229422022. View Article : Google Scholar : PubMed/NCBI
34	Hayashi H, Yasufuku I, Higashi T, Chikaishi W, Yokoi R, Fukada M, Sato Y, Asai R, Tajima JY, Saigo C, et al: Late recurrent gastric carcinoma 12 years after surgery with attenuation of CD44 variant 9 expression. Surg Case Rep. 9:872023. View Article : Google Scholar : PubMed/NCBI
35	Ishimoto T, Nagano O, Yae T, Tamada M, Motohara T, Oshima H, Oshima M, Ikeda T, Asaba R, Yagi H, et al: CD44 variant regulates redox status in cancer cells by stabilizing the xCT subunit of system xc(−) and thereby promotes tumor growth. Cancer Cell. 19:387–400. 2011. View Article : Google Scholar : PubMed/NCBI
36	Bertaux-Skeirik N, Wunderlich M, Teal E, Chakrabarti J, Biesiada J, Mahe M, Sundaram N, Gabre J, Hawkins J, Jian G, et al: CD44 variant isoform 9 emerges in response to injury and contributes to the regeneration of the gastric epithelium. J Pathol. 242:463–475. 2017. View Article : Google Scholar : PubMed/NCBI
37	Jang BI, Li Y, Graham DY and Cen P: The role of CD44 in the pathogenesis, diagnosis, and therapy of gastric cancer. Gut and Liver. 5:397–405. 2011. View Article : Google Scholar : PubMed/NCBI
38	Engevik AC, Feng R, Choi E, White S, Bertaux-Skeirik N, Li J, Mahe MM, Aihara E, Yang L, DiPasquale B, et al: The development of spasmolytic polypeptide/TFF2-expressing metaplasia (SPEM) during gastric repair is absent in the aged stomach. Cell Mol Gastroenterol Hepatol. 2:605–624. 2016. View Article : Google Scholar : PubMed/NCBI
39	Topham DJ and Reilly EC: Tissue-resident memory CD8+ T cells: From phenotype to function. Front Immunol. 9:5152018. View Article : Google Scholar : PubMed/NCBI
40	Yi P, Cao P, Yang M, Xiong F, Jiang J, Mei Y, Xin Y, Zhao M, Wu H and Lu Q: Overexpressed CD44 is associated with B-cell activation via the HA-CD44-AIM2 pathway in lupus B cells. Clin Immunol. 255:1097102023. View Article : Google Scholar : PubMed/NCBI
41	Zhang Q, Wang X, Liu Y, Xu H and Ye C: Pan-cancer and single-cell analyses identify CD44 as an immunotherapy response predictor and regulating macrophage polarization and tumor progression in colorectal cancer. Front Oncol. 14:13808212024. View Article : Google Scholar : PubMed/NCBI
42	Van Driel M, Günthert U, van Kessel AC, Joling P, Stauder R, Lokhorst HM and Bloem AC: CD44 variant isoforms are involved in plasma cell adhesion to bone marrow stromal cells. Leukemia. 16:135–143. 2002. View Article : Google Scholar : PubMed/NCBI
43	Johnson DE, O'Keefe RA and Grandis JR: Targeting the IL-6/JAK/STAT3 signalling axis in cancer. Nat Rev Clin Oncol. 15:234–248. 2018. View Article : Google Scholar : PubMed/NCBI
44	Fricke H, Hartmann J, Sitter T, Steldinger R, Rieber P and Schiffl H: Continuous ambulatory peritoneal dialysis impairs T lymphocyte selection in the peritoneum. Kidney Int. 49:1386–1395. 1996. View Article : Google Scholar : PubMed/NCBI
45	Cheung EC and Vousden KH: The role of ROS in tumour development and progression. Nat Rev Cancer. 22:280–297. 2022. View Article : Google Scholar : PubMed/NCBI
46	Pieters M, Kruger IM, Kruger HS, Breet Y, Moss SJ, van Oort A, Bester P and Ricci C: Strategies of modelling incident outcomes using cox regression to estimate the population attributable risk. Int J Environ Res Public Health. 20:64172023. View Article : Google Scholar : PubMed/NCBI
47	Sauerbrei W, Perperoglou A, Schmid M, Abrahamowicz M, Becher H, Binder H, Dunkler D, Harrell FE Jr, Royston P and Heinze G: State of the art in selection of variables and functional forms in multivariable analysis-outstanding issues. Diagn Progn Res. 4:32020. View Article : Google Scholar : PubMed/NCBI
48	Zhu N, Zhao Y, Yan W, Wei L, Sang Q, Li J, Liu B and Yu B: Characterization of alternative splicing events and prognostic signatures in gastric cancer. Cancer Cell Int. 24:1672024. View Article : Google Scholar : PubMed/NCBI
49	Cao M, Hu C, Pan S, Zhang Y, Yu P, Zhang R, Cheng X and Xu Z: Development and validation of nomogram for predicting early recurrence after radical gastrectomy of gastric cancer. World J Surg Oncol. 22:212024. View Article : Google Scholar : PubMed/NCBI
50	Cai H, Li M, Deng R, Wang M and Shi Y: Advances in molecular biomarkers research and clinical application progress for gastric cancer immunotherapy. Biomark Res. 10:672022. View Article : Google Scholar : PubMed/NCBI
51	Yang X and Li M, Qin X, Tan S, Du L, Ma C and Li M: Photophosphatidylserine guides natural killer cell photoimmunotherapy via TIM-3. J Am Chem Soc. 144:3863–3874. 2022. View Article : Google Scholar : PubMed/NCBI
52	Jiang J, Jin MS, Kong F, Cao D, Ma HX, Jia Z, Wang YP, Suo J and Cao X: Decreased galectin-9 and increased Tim-3 expression are related to poor prognosis in gastric cancer. PLoS One. 8:e817992013. View Article : Google Scholar : PubMed/NCBI
53	Zhou Y, Li S, Hu Y, Xu X, Cui J, Li S, Li Z, Ji J and Xing R: Multi-regional sequencing reveals the genetic and immune heterogeneity of non-cancerous tissues in gastric cancer. J Pathol. 263:454–465. 2024. View Article : Google Scholar : PubMed/NCBI
54	Wang YK, Lv XX, Wang ZQ, Zhou YM, Jiang B, Wang SN and Chen XD: The significance of the microlymphangiogenesis, microangiogenesis, and combined detection of programmed cell death-1 protein (PD-1)/ki67 in gastric cancer tissues. J Cancer Res Clin Oncol. 149:9129–9137. 2023. View Article : Google Scholar : PubMed/NCBI
55	Li L, Wu W, Zheng W, Hui Q and Zhao C: Analysis of the correlation between p27 expression and helicobacter pylori infection in gastric cancer. APMIS. 130:21–25. 2022. View Article : Google Scholar : PubMed/NCBI
56	Awadh M and Darwish A, Alqatari H, Buzaid FM and Darwish A: A descriptive analysis of gastric cancer with an immunohistochemical study of ki67 and p53 as prognostic factors.: Bahrain experience. Saudi Med J. 44:1300–1309. 2023. View Article : Google Scholar : PubMed/NCBI
57	Chen L, Hong J, Hu R, Yu X, Chen X, Zheng S, Qin Y, Zhou X, Wang Y, Zheng L, et al: Clinical value of combined detection of serum sTim-3 and pepsinogen for gastric cancer diagnosis. Cancer Manag Res. 13:7759–7769. 2021. View Article : Google Scholar : PubMed/NCBI
58	Wang H, Jin W, Wan C and Zhu C: Diagnostic value of combined detection of CA72-4, CA19-9, and carcinoembryonic antigen comparing to CA72-4 alone in gastric cancer: A systematic review and meta-analysis. Transl Cancer Res. 11:848–856. 2022. View Article : Google Scholar : PubMed/NCBI